Anesthesiology and Pain Medicine

Published by: Kowsar

The Effect of Intravenous Administration of Active Recombinant Factor VII on Postoperative Bleeding in Cardiac Valve Reoperations; A Randomized Clinical Trial

Narges Payani 1 , Mahnoosh Foroughi 2 and Ali Dabbagh 1 , *
Authors Information
1 Anesthesiology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Cardiovascular Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Article information
  • Anesthesiology and Pain Medicine: February 01, 2015, 5 (1); e22846
  • Published Online: February 1, 2015
  • Article Type: Research Article
  • Received: September 24, 2014
  • Revised: November 15, 2014
  • Accepted: November 23, 2014
  • DOI: 10.5812/aapm.22846

To Cite: Payani N, Foroughi M, Dabbagh A. The Effect of Intravenous Administration of Active Recombinant Factor VII on Postoperative Bleeding in Cardiac Valve Reoperations; A Randomized Clinical Trial, Anesth Pain Med. 2015 ; 5(1):e22846. doi: 10.5812/aapm.22846.

Abstract
Copyright © 2015, Iranian Society of Regional Anesthesia and Pain Medicine (ISRAPM). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Yank V, Tuohy CV, Logan AC, Bravata DM, Staudenmayer K, Eisenhut R, et al. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med. 2011; 154(8): 529-40[DOI][PubMed]
  • 2. Brown C, Joshi B, Faraday N, Shah A, Yuh D, Rade JJ, et al. Emergency cardiac surgery in patients with acute coronary syndromes: a review of the evidence and perioperative implications of medical and mechanical therapeutics. Anesth Analg. 2011; 112(4): 777-99[DOI][PubMed]
  • 3. Clark KB, Kon ND, Hammon JW, Jr., MacGregor DA, Kincaid EH, Reichert MG. Factor IX complex for the treatment of severe bleeding after cardiac surgery. J Cardiovasc Pharmacol. 2013; 62(1): 67-71[DOI][PubMed]
  • 4. Guzzetta NA, Russell IA, Williams GD. Review of the off-label use of recombinant activated factor VII in pediatric cardiac surgery patients. Anesth Analg. 2012; 115(2): 364-78[DOI][PubMed]
  • 5. Levy JH, Sniecinski RM. Prohemostatic treatment in cardiac surgery. Semin Thromb Hemost. 2012; 38(3): 237-43[DOI][PubMed]
  • 6. Vincent JL, Rossaint R, Riou B, Ozier Y, Zideman D, Spahn DR. Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding--a European perspective. Crit Care. 2006; 10(4)[DOI][PubMed]
  • 7. Spinella PC, Perkins JG, McLaughlin DF, Niles SE, Grathwohl KW, Beekley AC, et al. The effect of recombinant activated factor VII on mortality in combat-related casualties with severe trauma and massive transfusion. J Trauma. 2008; 64(2): 286-93[DOI][PubMed]
  • 8. Dabbagh A, Rajaei S, Bahadori Monfared A, Keramatinia AA, Omidi K. Cardiopulmonary Bypass, Inflammation and How to Defy it: Focus on Pharmacological Interventions. Iran J Pharm Res. 2012; 11(3): 705-14[PubMed]
  • 9. Dabbagh A, Rajaei S, Shamsolahrar MH. The effect of intravenous magnesium sulfate on acute postoperative bleeding in elective coronary artery bypass surgery. J Perianesth Nurs. 2010; 25(5): 290-5[DOI][PubMed]
  • 10. Berkhof FF, Eikenboom JC. Efficacy of recombinant activated Factor VII in patients with massive uncontrolled bleeding: a retrospective observational analysis. Transfusion. 2009; 49(3): 570-7[DOI][PubMed]
  • 11. Barnard J, Millner R. A review of topical hemostatic agents for use in cardiac surgery. Ann Thorac Surg. 2009; 88(4): 1377-83[DOI][PubMed]
  • 12. Beckerman Z, Shopen Y, Alon H, Cohen O, Nir RR, Adler Z, et al. Coronary artery bypass grafting after aprotinin: are we doing better? J Thorac Cardiovasc Surg. 2013; 145(1): 243-8[DOI][PubMed]
  • 13. Biancari F, Mikkola R, Heikkinen J, Lahtinen J, Airaksinen KE, Juvonen T. Estimating the risk of complications related to re-exploration for bleeding after adult cardiac surgery: a systematic review and meta-analysis. Eur J Cardiothorac Surg. 2012; 41(1): 50-5[DOI][PubMed]
  • 14. Lee GC, Kicza AM, Liu KY, Nyman CB, Kaufman RM, Body SC. Does rotational thromboelastometry (ROTEM) improve prediction of bleeding after cardiac surgery? Anesth Analg. 2012; 115(3): 499-506[DOI][PubMed]
  • 15. Pasquali SK, Li JS, He X, Jacobs ML, O'Brien SM, Hall M, et al. Comparative analysis of antifibrinolytic medications in pediatric heart surgery. J Thorac Cardiovasc Surg. 2012; 143(3): 550-7[DOI][PubMed]
  • 16. Vernick WJ, Woo JY. Anesthetic considerations during minimally invasive mitral valve surgery. Semin Cardiothorac Vasc Anesth. 2012; 16(1): 11-24[DOI][PubMed]
  • 17. Ho KM, Litton E. Cost-effectiveness of using recombinant activated factor VII as an off-label rescue treatment for critical bleeding requiring massive transfusion. Transfusion. 2012; 52(8): 1696-702[DOI][PubMed]
  • 18. Huang WY, Kruskall MS, Bauer KA, Uhl L, Shaz BH. The use of recombinant activated factor VII in three patients with central nervous system hemorrhages associated with factor VII deficiency. Transfusion. 2004; 44(11): 1562-6[DOI][PubMed]
  • 19. Warren OJ, Alcock EM, Choong AM, Leff DR, Van Herzeele I, Darzi AW, et al. Recombinant activated factor VII: a solution to refractory haemorrhage in vascular surgery? Eur J Vasc Endovasc Surg. 2008; 35(2): 145-52[DOI][PubMed]
  • 20. Pychynska-Pokorska M, Pagowska-Klimek I, Krajewski W, Moll JJ. Use of recombinant activated factor VII for controlling refractory postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2011; 25(6): 987-94[DOI][PubMed]
  • 21. Dell'Amore A, Caroli G, Nizar A, Cassanelli N, Luciano G, Greco D, et al. Can topical application of tranexamic acid reduce blood loss in thoracic surgery? A prospective randomised double blind investigation. Heart Lung Circ. 2012; 21(11): 706-10[DOI][PubMed]
  • 22. Jeganathan R, Armstrong S, Al-Alao B, David T. The risk and outcomes of reoperative tricuspid valve surgery. Ann Thorac Surg. 2013; 95(1): 119-24[DOI][PubMed]
  • 23. Okonta KE, Edwin F, Falase B. Is recombinant activated factor VII effective in the treatment of excessive bleeding after paediatric cardiac surgery? Interact Cardiovasc Thorac Surg. 2012; 15(4): 690-4[DOI][PubMed]
  • 24. Uber WE, Toole JM, Stroud MR, Haney JS, Lazarchick J, Crawford FA, Jr., et al. Administration of recombinant activated factor VII in the intensive care unit after complex cardiovascular surgery: clinical and economic outcomes. J Thorac Cardiovasc Surg. 2011; 141(6): 1469-77 e2[DOI][PubMed]
  • 25. Diringer MN, Skolnick BE, Mayer SA, Steiner T, Davis SM, Brun NC, et al. Risk of thromboembolic events in controlled trials of rFVIIa in spontaneous intracerebral hemorrhage. Stroke. 2008; 39(3): 850-6[DOI][PubMed]
  • 26. Yuan ZH, Jiang JK, Huang WD, Pan J, Zhu JY, Wang JZ. A meta-analysis of the efficacy and safety of recombinant activated factor VII for patients with acute intracerebral hemorrhage without hemophilia. J Clin Neurosci. 2010; 17(6): 685-93[DOI][PubMed]
  • 27. Bauza G, Hirsch E, Burke P, Quillen K. Low-dose recombinant activated factor VII in massively transfused trauma patients with coagulopathy. Transfusion. 2007; 47(4): 749-51[DOI][PubMed]
  • 28. Bhaskar B, Zeigenfuss M, Choudhary J, Fraser JF. Use of recombinant activated Factor VII for refractory after lung transplant bleeding as an effective strategy to restrict blood transfusion and associated complications. Transfusion. 2013; 53(4): 798-804[DOI][PubMed]
  • 29. Boffard KD, Choong PI, Kluger Y, Riou B, Rizoli SB, Rossaint R, et al. The treatment of bleeding is to stop the bleeding! Treatment of trauma-related hemorrhage. Transfusion. 2009; 49 Suppl 5: 240S-7S[DOI][PubMed]
  • 30. Levi M, Peters M, Buller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med. 2005; 33(4): 883-90[PubMed]
  • 31. O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA. 2006; 295(3): 293-8[DOI][PubMed]
  • 32. Johansson PI. Off-label use of recombinant factor VIIa for treatment of haemorrhage: results from randomized clinical trials. Vox Sang. 2008; 95(1): 1-7[DOI][PubMed]
  • 33. Wittenstein B, Ng C, Ravn H, Goldman A. Recombinant factor VII for severe bleeding during extracorporeal membrane oxygenation following open heart surgery. Pediatr Crit Care Med. 2005; 6(4): 473-6[DOI][PubMed]
  • 34. Benharash P, Bongard F, Putnam B. Use of recombinant factor VIIa for adjunctive hemorrhage control in trauma and surgical patients. Am Surg. 2005; 71(9): 776-80[PubMed]
  • 35. Boffard KD, Riou B, Warren B, Choong PI, Rizoli S, Rossaint R, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma. 2005; 59(1): 8-15[PubMed]
  • 36. Clark AD, Gordon WC, Walker ID, Tait RC. 'Last-ditch' use of recombinant factor VIIa in patients with massive haemorrhage is ineffective. Vox Sang. 2004; 86(2): 120-4[DOI][PubMed]
  • 37. Duchesne JC, Mathew KA, Marr AB, Pinsky MR, Barbeau JM, McSwain NE. Current evidence based guidelines for factor VIIa use in trauma: the good, the bad, and the ugly. Am Surg. 2008; 74(12): 1159-65[PubMed]
  • 38. Stanworth SJ, Birchall J, Doree CJ, Hyde C. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev. 2007; (2)[DOI][PubMed]
  • 39. Simpson E, Lin Y, Stanworth S, Birchall J, Doree C, Hyde C. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev. 2012; 3[DOI][PubMed]
  • 40. Gill R, Herbertson M, Vuylsteke A, Olsen PS, von Heymann C, Mythen M, et al. Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery. Circulation. 2009; 120(1): 21-7[DOI][PubMed]
  • 41. von Heymann C, Jonas S, Spies C, Wernecke KD, Ziemer S, Janssen D, et al. Recombinant activated factor VIIa for the treatment of bleeding in major abdominal surgery including vascular and urological surgery: a review and meta-analysis of published data. Crit Care. 2008; 12(1)[DOI][PubMed]
  • 42. von Heymann C, Hotz H, Konertz W, Kox WJ, Spies C. Successful treatment of refractory bleeding with recombinant factor VIIa after redo coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth. 2002; 16(5): 615-6[PubMed]
  • 43. von Heymann C, Redlich U, Jain U, Kastrup M, Schroeder T, Sander M, et al. Recombinant activated factor VII for refractory bleeding after cardiac surgery--a retrospective analysis of safety and efficacy. Crit Care Med. 2005; 33(10): 2241-6[PubMed]
  • 44. von Heymann C, Schoenfeld H, Sander M, Ziemer S, Grubitzsch H, Spies C. Clopidogrel-related refractory bleeding after coronary artery bypass graft surgery: a rationale for the use of coagulation factor concentrates? Heart Surg Forum. 2005; 8(1)-41[DOI][PubMed]
  • 45. Diprose P, Herbertson MJ, O'Shaughnessy D, Gill RS. Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study. Br J Anaesth. 2005; 95(5): 596-602[DOI][PubMed]
  • 46. Richardson A, Herbertson M, Gill R. The role of recombinant activated factor VII in cardiac surgery. HSR Proc Intensive Care Cardiovasc Anesth. 2009; 1(3): 9-12[DOI][PubMed]
  • 47. Warren OJ, Rogers PL, Watret AL, de Wit KL, Darzi AW, Gill R, et al. Defining the role of recombinant activated factor VII in pediatric cardiac surgery: where should we go from here? Pediatr Crit Care Med. 2009; 10(5): 572-82[DOI][PubMed]
  • 48. Hardy JF, Belisle S, Van der Linden P. Efficacy and safety of activated recombinant factor VII in cardiac surgical patients. Curr Opin Anaesthesiol. 2009; 22(1): 95-9[DOI][PubMed]
  • 49. Levy JH, Tanaka KA. Prohemostatic agents to prevent perioperative blood loss. Semin Thromb Hemost. 2008; 34(5): 439-44[DOI][PubMed]
  • 50. Ranucci M, Baryshnikova E, Colella D. Monitoring prohemostatic treatment in bleeding patients. Semin Thromb Hemost. 2012; 38(3): 282-91[DOI][PubMed]
  • 51. Ranucci M, Isgro G, Soro G, Conti D, De Toffol B. Efficacy and safety of recombinant activated factor vii in major surgical procedures: systematic review and meta-analysis of randomized clinical trials. Arch Surg. 2008; 143(3): 296-304[DOI][PubMed]
  • 52. Roberts HR, Monroe DM, 3rd, Hoffman M. Safety profile of recombinant factor VIIa. Semin Hematol. 2004; 41(1 Suppl 1): 101-8[DOI][PubMed]
  • 53. Chapman AJ, Blount AL, Davis AT, Hooker RL. Recombinant factor VIIa (NovoSeven RT) use in high risk cardiac surgery. Eur J Cardiothorac Surg. 2011; 40(6): 1314-8[DOI][PubMed]
  • 54. Karkouti K, Beattie WS, Crowther MA, Callum JL, Chun R, Fremes SE, et al. The role of recombinant factor VIIa in on-pump cardiac surgery: proceedings of the Canadian Consensus Conference. Can J Anaesth. 2007; 54(7): 573-82[DOI][PubMed]
  • 55. Sattler S, Schwartz A. Does the use of recombinant factor VIIA reduce morbidity or mortality in nonhemophiliac patients? Ann Emerg Med. 2012; 60(2): 160-1[DOI][PubMed]
  • 56. Porte RJ, Leebeek FW. Pharmacological strategies to decrease transfusion requirements in patients undergoing surgery. Drugs. 2002; 62(15): 2193-211[PubMed]
  • 57. Society of Thoracic Surgeons Blood Conservation Guideline Task F, Ferraris VA, Ferraris SP, Saha SP, Hessel E2, Haan CK, et al. Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg. 2007; 83(5 Suppl)-86[DOI][PubMed]
  • 58. Vamvakas EC, Blajchman MA. Blood still kills: six strategies to further reduce allogeneic blood transfusion-related mortality. Transfus Med Rev. 2010; 24(2): 77-124[DOI][PubMed]
  • 59. Vamvakas EC, Blajchman MA. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood. 2009; 113(15): 3406-17[DOI][PubMed]
  • 60. Vamvakas EC. Relative safety of pooled whole blood-derived versus single-donor (apheresis) platelets in the United States: a systematic review of disparate risks. Transfusion. 2009; 49(12): 2743-58[DOI][PubMed]
  • 61. Vamvakas EC. Reasons for moving toward a patient-centric paradigm of clinical transfusion medicine practice. Transfusion. 2013; 53(4): 888-901[DOI][PubMed]
  • 62. Tayebi Meybodi K, Taghvaei M, Derakhshanrad N, Khan ZH, Saberi H. Recombinant Activated Factor VII, as a Remedy for Intractable Coagulopathy Following Massive Transfusion in a Case of Giant Cranial Neurofibroma. Arch Neurosci. 2014; 2(2)[DOI]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments